Абатацепт
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Intravenozno, subkutano |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 16,7 (12-23) dana |
| Identifikatori | |
| CAS број | 332348-12-6  |
| ATC kod | L04AA24 (WHO) |
| DrugBank | DB01281 |
| ChEMBL | CHEMBL1201823 |
Abatacept (Orencia) fuzioni protein je koji se sastoji od Fc regiona imunoglobulina IgG1 spojenog sa ekstracelularnim domenom CTLA-4. Ovaj molekul ima veću sposobnost vezivanja za CD80 (B7-1) nego za CD86 (B7-2). Abatacept je selektivni kostimulationi modulator koji inhibira kostimulaciju T ćelija. On se koristi za lečenje reumatoidnog artritisa u slučaju neadekvatnog responsa na anti-TNFα terapiju.[1][2][3][4][5][6][7][8][9][10][11][12]
Reference
[уреди | уреди извор]- ^ Dall'Era M, Davis J: CTLA4Ig: a novel inhibitor of costimulation. Lupus. 2004;13(5):372-6. PMID 15230295
- ^ Moreland L, Bate G, Kirkpatrick P: Abatacept. Nat Rev Drug Discov. 2006 Mar;5(3):185-6. PMID 16557658
- ^ Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland LW: Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006 Nov;33(11):2162-6. Epub 2006 Oct 1. PMID 17014006
- ^ Weyand CM, Goronzy JJ: T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006 Apr;2(4):201-10. PMID 16932686
- ^ Scheinfeld N: Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists. J Dermatolog Treat. 2006;17(4):229-34. PMID 16971318
- ^ Maxwell LJ, Singh JA: Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010 Feb;37(2):234-45. Epub 2010 Jan 15. PMID 20080922
- ^ Maxwell L, Singh JA: Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007277. PMID 19821401
- ^ Nogid A, Pham DQ: Role of abatacept in the management of rheumatoid arthritis. Clin Ther. 2006 Nov;28(11):1764-78. PMID 17212998
- ^ Hervey PS, Keam SJ: Abatacept. BioDrugs. 2006;20(1):53-61; discussion 62. PMID 16573350
- ^ Reynolds J, Shojania K, Marra CA: Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. Pharmacotherapy. 2007 Dec;27(12):1693-701. PMID 18041889
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
